Cargando…

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy

Epstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bian, Jin, Niu, Yan, Ma, Yanli, Chen, Fuhua, Ma, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813251/ https://www.ncbi.nlm.nih.gov/pubmed/35126664 http://dx.doi.org/10.1155/2022/8537966

Ejemplares similares

Retracted: A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
por: Smith, Corey, et al.
Publicado: (2021)

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
por: Lim, Darren Wan-Teck, et al.
Publicado: (2023)

Functional Inactivation of EBV-Specific T-Lymphocytes in Nasopharyngeal Carcinoma: Implications for Tumor Immunotherapy
por: Li, Jiang, et al.
Publicado: (2007)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Multimodality Management of EBV-Associated Nasopharyngeal Carcinoma
por: Yu, Justin, et al.
Publicado: (2021)

Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma
por: Li, Wenting, et al.
Publicado: (2023)

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
por: Zhou, Yajuan, et al.
Publicado: (2017)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
por: Fang, Wenfeng, et al.
Publicado: (2014)

EBV based cancer prevention and therapy in nasopharyngeal carcinoma
por: Cao, Ya
Publicado: (2017)

Updates on Epstein–Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV
por: Ahmed, Naveed, et al.
Publicado: (2022)

EBV-associated gastric carcinoma in high- and low-incidence areas for nasopharyngeal carcinoma
por: Boysen, T, et al.
Publicado: (2009)

Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
por: Xu, Liqin, et al.
Publicado: (2022)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

A Therapeutic Approach to Nasopharyngeal Carcinomas by DNAzymes Targeting EBV LMP-1 Gene
por: Yang, Lifang, et al.
Publicado: (2010)

Monoamine oxidase A is down-regulated in EBV-associated nasopharyngeal carcinoma
por: Lee, Hui Min, et al.
Publicado: (2020)

The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis
por: Liu, Weixing, et al.
Publicado: (2021)

Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma
por: Zhou, Han, et al.
Publicado: (2020)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Analysis of Epstein–Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region
por: Dias, Josiane M., et al.
Publicado: (2022)

The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection
por: Guo, Can, et al.
Publicado: (2006)

CD44+ Cancer Stem-Like Cells in EBV-Associated Nasopharyngeal Carcinoma
por: Lun, Samantha Wei-Man, et al.
Publicado: (2012)

EBV-Associated Hub Genes as Potential Biomarkers for Predicting the Prognosis of Nasopharyngeal Carcinoma
por: Ding, Tengteng, et al.
Publicado: (2023)

EBV-encoded RNA via TLR3 induces inflammation in nasopharyngeal carcinoma
por: Li, Zhi, et al.
Publicado: (2015)

Meta-analysis of nasopharyngeal carcinoma microarray data explores mechanism of EBV-regulated neoplastic transformation
por: Chen, Xia, et al.
Publicado: (2008)

Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer
por: Ngan, Hoi-Lam, et al.
Publicado: (2018)

Pathogenesis and Diagnostic Significance of EBV-miR-BARTs in Nasopharyngeal Carcinoma
por: Wu, Zhen, et al.
Publicado: (2022)

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
por: Jiang, Mingxia, et al.
Publicado: (2021)

Systematic comparison of plasma EBV DNA, anti‐EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma
por: Tan, Lu Ping, et al.
Publicado: (2019)

Differential expression of EBV proteins LMP1 and BHFR1 in EBV-associated gastric and nasopharyngeal cancer tissues
por: WANG, AILIANG, et al.
Publicado: (2016)

EBV‐encoded miRNAs target ATM‐mediated response in nasopharyngeal carcinoma
por: Lung, Raymond W‐M, et al.
Publicado: (2018)

Circulation EBV Mir-Bart-7 Relating to Clinical Manifestation in Nasopharyngeal Carcinoma
por: Wardana, Tirta, et al.
Publicado: (2020)

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
por: Ma, Guofeng, et al.
Publicado: (2021)

Current issues and perspectives in PD-1 blockade cancer immunotherapy
por: Chamoto, Kenji, et al.
Publicado: (2020)

Immune metabolism in PD-1 blockade-based cancer immunotherapy
por: Kumar, Alok, et al.
Publicado: (2020)

Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma
por: Li, Le, et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma
por: Ye, Qian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5695trdfcvm91gn7fp1dq5h70b